Immunotherapeutics
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
247
NCT05163080
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 18, 2021
Completion: Aug 18, 2024
Loading map...